FDA approves bictegravir and lenacapavir for HIV
-
By
-
Kathryn Wighton
-
August 28, 2026
-
2 min
Clinical Report: FDA approves bictegravir and lenacapavir for HIV
Overview
The FDA has approved bictegravir and lenacapavir (Bixlenvo) for adults with HIV-1 who are virologically suppressed. This once-daily tablet regimen was evaluated in clinical trials.
Background
The approval of Bixlenvo is based on its high barrier to resistance and lack of cross-resistance to other therapies.
Data Highlights
| Trial | Virologic Suppression at 48 Weeks | Participants |
|---|---|---|
| ARTISTRY-1 | 1% (3/372) on Bixlenvo | 372 |
| ARTISTRY-1 | 1% (2/186) on complex regimens | 186 |
Key Findings
- Bictegravir and lenacapavir approved for adults with HIV-1 RNA < 50 copies/mL.
- Approval based on ARTISTRY-1 and ARTISTRY-2 trials showing non-inferiority in virologic suppression.
- Participants in ARTISTRY-1 had a median age of 60 years and a median HIV treatment duration of 28 years.
- 67% of participants had nucleoside reverse transcriptase inhibitor resistance.
- Common adverse reactions included headache, nausea, and diarrhea.
Clinical Implications
Clinicians may consider Bixlenvo for patients who are virologically suppressed and have no known resistance.
Conclusion
The approval of Bixlenvo provides a new treatment option for patients requiring a change in their antiretroviral therapy.
Related Resources & Content
- Gilead Sciences, Inc. - U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
- Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
- Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2)
- MDSpire News — Lenacapavir Demonstrates 100% Efficacy in Preventing HIV Infection in Women
- MDSpire News — Two-Drug HIV Regimen Gains FDA Approval
- Open Forum Infectious Diseases — Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study
- The Journal of Infectious Diseases — Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years
- Lenacapavir Demonstrates 100% Efficacy in Preventing HIV Infection in Women
- Two-Drug HIV Regimen Gains FDA Approval
- Gilead Sciences, Inc. - U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
- FDA-Approved HIV Medicines | NIH
- Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
- Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial - ScienceDirect
- HIV/AIDS Treatment Guidelines | Clinicalinfo.HIV.gov
- Optimizing Antiretroviral Therapy in the Setting of Viral Suppression
- Laboratory Testing: Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring | NIH
Based on findings from:
FDA approves bictegravir and lenacapavir for HIV
Kathryn Wighton. MDSpire News, 2026.
https://news.mdspire.com/internal-medicine/articles/fda-approves-bictegravir-and-lenacapavir-for-hiv/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
